1297 related articles for article (PubMed ID: 33917481)
21. Potential inhibitors of SARS-CoV-2: recent advances.
Jamalipour Soufi G; Iravani S
J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
[TBL] [Abstract][Full Text] [Related]
22. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
Kettunen P; Lesnikova A; Räsänen N; Ojha R; Palmunen L; Laakso M; Lehtonen Š; Kuusisto J; Pietiläinen O; Saber SH; Joensuu M; Vapalahti OP; Koistinaho J; Rolova T; Balistreri G
J Virol; 2023 Apr; 97(4):e0014423. PubMed ID: 37039676
[TBL] [Abstract][Full Text] [Related]
24. [Basic information of Coronavirus].
Kamitani W
Uirusu; 2020; 70(1):29-36. PubMed ID: 33967109
[TBL] [Abstract][Full Text] [Related]
25. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
26. Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies.
Troyer Z; Alhusaini N; Tabler CO; Sweet T; de Carvalho KIL; Schlatzer DM; Carias L; King CL; Matreyek K; Tilton JC
J Extracell Vesicles; 2021 Jun; 10(8):e12112. PubMed ID: 34188786
[TBL] [Abstract][Full Text] [Related]
27. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
28. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.
Yapasert R; Khaw-On P; Banjerdpongchai R
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946543
[TBL] [Abstract][Full Text] [Related]
29. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
30. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
31. Structural biology of SARS-CoV-2: open the door for novel therapies.
Yan W; Zheng Y; Zeng X; He B; Cheng W
Signal Transduct Target Ther; 2022 Jan; 7(1):26. PubMed ID: 35087058
[TBL] [Abstract][Full Text] [Related]
32. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
33. Classical and alternative receptors for SARS-CoV-2 therapeutic strategy.
Masre SF; Jufri NF; Ibrahim FW; Abdul Raub SH
Rev Med Virol; 2021 Sep; 31(5):1-9. PubMed ID: 33368788
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim-1, and NRP-1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems.
Zhang F; Li W; Feng J; Ramos da Silva S; Ju E; Zhang H; Chang Y; Moore PS; Guo H; Gao SJ
J Med Virol; 2021 Dec; 93(12):6671-6685. PubMed ID: 34324210
[TBL] [Abstract][Full Text] [Related]
35. Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption.
Ren W; Lan J; Ju X; Gong M; Long Q; Zhu Z; Yu Y; Wu J; Zhong J; Zhang R; Fan S; Zhong G; Huang A; Wang X; Ding Q
PLoS Pathog; 2021 Nov; 17(11):e1010053. PubMed ID: 34748603
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
37. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
38. The structural basis of accelerated host cell entry by SARS-CoV-2†.
Seyran M; Takayama K; Uversky VN; Lundstrom K; Palù G; Sherchan SP; Attrish D; Rezaei N; Aljabali AAA; Ghosh S; Pizzol D; Chauhan G; Adadi P; Mohamed Abd El-Aziz T; Soares AG; Kandimalla R; Tambuwala M; Hassan SS; Azad GK; Pal Choudhury P; Baetas-da-Cruz W; Serrano-Aroca Á; Brufsky AM; Uhal BD
FEBS J; 2021 Sep; 288(17):5010-5020. PubMed ID: 33264497
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions.
Lin H; Cherukupalli S; Feng D; Gao S; Kang D; Zhan P; Liu X
Curr Med Chem; 2022; 29(4):682-699. PubMed ID: 33881969
[TBL] [Abstract][Full Text] [Related]
40. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling.
Frolova EI; Palchevska O; Lukash T; Dominguez F; Britt W; Frolov I
J Virol; 2022 Aug; 96(15):e0075322. PubMed ID: 35876526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
